Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and raises the price target from $46 to $51.
March 01, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals and raises the price target from $46 to $51.
The increase in price target by a reputable analyst like Laura Chico from Wedbush signals a strong confidence in Xenon Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100